The biotechnology industry is expected to increase the production of new biopharmaceuticals.1 Biopharmaceuticals require high-quality standards, high initial investments for approval and introduction into the market as well as continued investment in manufacturing.2,3
List view / Grid view
The importance of critical quality attributes in Quality by Design for rapid bioprocess development strategies
QbD and PAT could revolutionise the way biopharma industries operate by cutting down their attrition rates, which could drastically change their business model. This article considers the issues involved.
18 August 2015 | By Victoria White
An international study of people with a family history of cancer has shown that a regular dose of aspirin reduces the long-term risk of the disease...
3 July 2015 | By European Pharmaceutical Review
In this PCR in-depth focus: Mikael Kubista from TATAA Biocenter addresses biological heterogeneity with single cell profiling, a look at quantitative PCR in the assessment of novel hepatic cell models, plus Q&A with Bio-Rad’s Javier Alba...
17 April 2013 | By European Pharmaceutical Review
In this Stem Cells In-Depth Focus: The promise held by induced pluripotent stem cells for research and regenerative medicine; Workshop preview – Cell based assays for screening; Cardiac stem cells; Stem Cells Roundtable...
From data to knowledge through smart Process Analytical Technologies (PAT) and process systems engineering
3 December 2008 | By
Pharma-Chem and bio-pharma development and production are now being profoundly influenced by the FDA PAT1 initiative with spectroscopic instrumentation being increasingly applied, or at the very least explored in product and process development and for on-line real-time process applications. The issues related to robust spectroscopic data analysis and calibration modelling…